The former CEO of 23andme has been appointed to regain control Genetic The test company is at the forefront of a $ 305 million offer without profitability, as it topped its pharmaceutical company at the bankruptcy auction.
Last month, Regeneron Pharmaceuticals agreed to buy the company for $ 256 million, as it tops an offer of $ 146 million from Anne WojCikki and TTAM Institute for Non -profit research. He paid the largest wojcicki to raise it by supporting Fortune 500, according to the former CEO. The company said on Friday that the deal is expected to be closed in the coming weeks after a court hearing on June 17.
WoJCICKI gave many bids to take the private company while the CEO remains. The company’s council rejected it every time, and all its independent managers resigned in response to in response to attempts to acquire it.
Once on Trailblazer in the original DNA test, 23andme submitted a bankruptcy in March, in an effort to sell its business at an auction after the demand for the demand and the violation of 2023 data that has been subjected to genetic information and a sensitive personality to millions of customers.
23andme has been a large part of customers since the bankruptcy announcement, with the threat of selling the most sensitive information to users – the entire genome sequence of the person – to an unknown buyer waving on the horizon. The company said that about 15 % of its current customers asked to close their accounts in response to bankruptcy and sale of them. Experts advised customers to request the company to delete their DNA data to protect privacy. TTAM said on Friday that he will support the current privacy policies of 23andme and comply with all the applicable data protection laws. Earlier this week, New York and more than twenty American states filed a lawsuit against 23andme to challenge the sale of private information to its customers.
After promoting the newsletter
Regeneron said he was ready to make a new offer, but he wanted to disintegrate fees of $ 10 million if the WoJCICKKI offer was accepted at the end.
